Absence of CYLD, which encodes a deubiquitinating enzyme, causes an inherited disease characterized by benign skin tumors. In this issue of Cell, Massoumi et al. (2006) show that CYLD deubiquitinates the coactivator Bcl-3, thereby preventing its translocation into the nucleus, where it normally interacts with NF-κB and activates transcription of proliferation genes in response to growth signals. 644 Cell 125, May 19, 2006 ©2006 Elsevier Inc.
orchestrates a restructuring of the chromosome into an axial filament. In the formation of an axial filament the chromosome extends all the way to the cell poles and its distribution in the cell narrows. It is possible that RacA both promotes the movement of DisA along the chromosome and facilitates the detection of DNA lesions.
After the first identification of a checkpoint in the bacterium Escherichia coli (Defais et al., 1971) , the characterization of checkpoint mechanisms has been largely confined to eukaryotic cells. The new work shows that the study of checkpoints in prokaryotes is far from exhausted. Future work may establish whether there are surveillance mechanisms in eukaryotes that mirror the dynamic behavior of DisA in scanning the genome for damage.
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Bejerano-Sagie, M., Oppenheimer-Shaanan, Y., Berlatzky, I., Rouvinski, A., Meyerovich, M., and Ben-Yehuda, S. (2006 Ubiquitin signaling regulates a wide variety of cellular processes, including degradation of proteins, receptor endocytosis, DNA repair, gene transcription, virus budding, the cell cycle, inflammation, and immune responses (Haglund and Dikic, 2005) . Many of these functions are dependent on the action of ubiquitin E3 ligases, which catalyze the transfer of ubiquitin to a protein substrate, leading to distinct types of ubiquitin modifications of target proteins (such as monoubiquitination and polyubiquitination). Protein ubiquitination is a reversible process: Ubiquitin can be cleaved from its protein substrates by deubiquitinating enzymes (DUBs), also known as deubiquitinases. Thus, similar to protein phosphorylation, regulated ubiquitination and deubiquitination of specific substrates are instrumental in cellular signaling in vivo (Haglund and Dikic, 2005) . Therefore, it is not surprising that identification of substrates of E3 ligases and DUBs is a key step for better understanding many different biological functions. In this issue of Cell, Massoumi et al. (2006) provide molecular insight into the function of the deubiquitinase CYLD.
CYLD is a tumor suppressor gene mutated in familial cylindromatosis, also called "turban tumor syndrome," an autosomal-dominant condition that predisposes to multiple skin tumors (Bignell et al., 2000) . The gene product, CYLD, is a DUB recently implicated in modulation of the NF-κB pathway, a crucial mediator of immune responses and inflammation. Activation of the NF-κB master transcription factor is thought to occur via either a classical or an alternative pathway (Hayden and Ghosh, 2004) inhibitor of NF-κB). Degradation of IκB releases p50-p65 NF-κB dimers to activate target-gene transcription.
In the alternative pathway, the signal is strictly dependent on certain TNF family members and the intracellular signal is mediated by homodimers of IKK-α. This results in the subsequent liberation of NF-κB dimers (mostly p52/REL-B dimers) into the nucleus (Hayden and Ghosh, 2004) (Figure 1) . A series of recent reports have shown that CYLD blocks signal transmission through the classical NF-κB cascade by deubiquitinating the TNF receptor-associated factor 2 (TRAF2), TRAF6, and IKK-γ (NEMO) (Trompouki et al., 2003; Brummelkamp et al., 2003; Kovalenko et al., 2003) . Notably, RNA interference of CYLD caused an increase in NF-κB activation when the pathway was stimulated by phorbol 12-myristate 13-acetate (PMA), CD40 ligands, or tumor necrosis factor α (TNF-α). Although these studies indicated that the CYLD deubiquitinating activity inhibits the NF-κB pathway, the regulatory mechanisms of CYLD catalytic activity and the physiological function of CYLD in vivo have remained largely unknown.
In this issue of Cell, Massoumi and colleagues (2006) created Cyld-deficient mice and examined the effects of phorbol diester 12-O-tetradecanoylphorbol 13-acetate (TPA) and UV treatments on keratinocytes. The phenotype observed in the Cyld-deficient mice-high sensitivity to skin tumor development-mimics the pathogenesis of familial cylindromatosis. Furthermore, loss of CYLD in keratinocytes did not affect the transcription induced by the classical p65-p50 NF-κB dimers but had clear effects on Bcl-3-linked p50-or p52-dependent gene regulation. Bcl-3 acts as a nuclear coactivator that switches the transcriptional properties of NF-κB p50 and p52 homodimers from a repressive to an active state (Watanabe et al., 1997) . The authors demonstrated that in normal keratinocytes, TPA or UV light triggers the translocation of CYLD from the cytoplasm to the perinuclear region, where CYLD binds and deubiquitinates Bcl-3, thereby preventing its nuclear accumulation. In Cyld-deficient keratinocytes, Bcl-3 accumulates in the nucleus, activates NF-κB by interacting with either p50 or p52, and induces transcription of NF-κB target genes such as cyclin D1. Nevertheless, it is not fully understood at the molecular level how Lys63-linked polyubiquitination of Bcl-3 is regulated and how this modification drives its nuclear translocation and interaction with the NF-κB p50 and p52 subunits in the nucleus. The components involved in recognition and translocation of Bcl-3 into the nucleus will help to trace the upstream and downstream components of this pathway.
What is clear from this study, however, is that the CYLD/Bcl-3 interaction is not involved in the classical NF-κB pathway in keratinocytes. This leaves open the question of whether p50-Bcl-3 and p52-Bcl-3 complexes are regulated via the NF-κB alternative pathway or whether they form a new regulatory pathway that is independent from both the classical and alternative pathways (Figure 1 ). To address these questions, it would be necessary to determine whether the alternative pathway is activated during skin tumor development. This can be addressed by examining the activation status of IKK proteins or their involvement in cyclin D1 regulation upon treatment with TPA or UV.
Further insights into the role of Bcl-3 in pathogenesis of cylindromatosis can be gained from analyzing Bcl-3-deficient mice (Franzoso et al., 1997) . These mice develop normally and reveal no gross macroscopic abnormalities, but they show an impaired architecture in the spleen and lymph nodes and dysregulation of T and B cells functions. Whether the increased nuclear accumulation of Bcl-3 and the elevated occupation of the NF-κB binding site of the cyclin D1 promoter are indeed major factors Target proteins of CYLD differ in each signaling pathway. In the classical pathway (left), NF-κB is activated by cytokines or viruses, which lead to proteasomal degradation of IκB-α following its phosphorylation by the IKK complex and Lys48-linked polyubiquitination. Targets of CYLD in the classical pathway are TRAFs and IKK-γ. The alternative pathway (middle) is mediated by NIK and IKK-α, resulting in p52-REL-B complex formation, which controls expression of NF-κB target genes. In keratinocytes (right), TPAinduced ubiquitination of Bcl-3 is required for its nuclear translocation and induction of cyclin D1 gene expression. CYLD deubiquitinates and inhibits Bcl-3 function in this newly discovered pathway.
responsible for the proliferation of Cyld-deficient keratinocytes can be examined in Bcl-3-deficient mice following TPA and UV stimulation. The authors already indicate such a possibility by showing that the depletion of Bcl-3 by small interfering RNA reduced cyclin D1 promoter activation induced by TPA and reversed the increased proliferation rate of Cyld-deficient keratinocytes.
Interestingly, a recent report by Reiley et al. (2006) describes a new regulatory role for CYLD in T cell receptor (TCR) signaling. Cyld-deficient mice are impaired in thymocyte development due to aberrations in the transition of double-positive to single-positive T cells. Contrary to the finding in keratinocytes, there are no defects in TNF-receptor-induced NF-κB signaling in bone-marrowderived macrophages of Cyld-deficient mice. The fact that there are differences in CYLD function in thymocytes and keratinocytes points to receptor-specific and cell-type-specific functions of CYLD. The regulation of CYLD deubiquitinating activity, which is not completely understood, awaits further experimental confirmation in distinct cell types. At the same time, the understanding of keratinocyte-specific signaling mediated by CYLD provides a greater opportunity to develop therapeutic agents for cylindromatosis. Potential agents include nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and natural compounds (e.g., ginseng extract and green-tea extract), all of which can inhibit activation of NF-κB. These anti-inflammatory agents and CYLD have a similar effect on NF-κB signaling, even though they act on different targets in the pathway. Topical application of aspirin has already entered clinical trials for the treatment of cylindromatosis. It is worth testing whether aspirin's efficacy in treating cylindromatosis depends on interfering with the Bcl-3 pathway as well. This study and the excitement in the field of NF-κB and cancer pathogenesis promise to foster the design of better therapeutics for cylindromatosis patients. 
